AGTR1 and Myocardial fibrosis: Hence, inhibition of the RAAS pathway, such as blocking the Ang II type 1 receptor (AT1R), has proven to be an effective strategy for the current clinical treatment of myocardial fibrosis as well as for improving myocardial dysfunction [18].